Esperion Therapeutics, maker of nexlizet and nexletol, the only statin alternatives in the market will receive a buyout offer for $10 Billion from a previously-established partnership between pharmaceutical giants Merck and Daiichi Sankyo

>>60647591 (OP)
>buyout
You have any claim to substantiate that? Every biotech stock seems to be on its way to being bought out.

>>60647591 (OP)
post proof of your insider trading bullshit so we can proceed

>>60647591 (OP)
been in merck since before the doggy shots were released. I have just seen them going down.

Is this good? Price go to 10 billion? Or is this bad and investors lose all their money?

>>60647893
OP is claiming a 40x.

>>60647913
That's, just put 5k in.

>>60648022
>That's, just put 5k in.
I have doubts. OP claims both Merck and Daiichi Sankyo have previously established partnerships, but there's no history of Merck ever doing such a thing, but Daiichi Sankyo has.

A half-truth, or half-lie?